Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Net Income
Bottom-line profit after all expenses, interest, and taxes.
Stoke Therapeutics, Inc.NASDAQ: STOK
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$50M, compared with $112.88M a year earlier. Trailing-twelve-month net income was -$169.77M.
Context
- Net income amounted to 3.7% of revenue in FY2025, down 239.7 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$231.33M (-3259.9%) for the fiscal year ending Dec 2026, a slowdown from the +92.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$50M+13.7% QoQ
- Last fiscal yearDec 2025
- -$6.89M+92.3% YoY
- LTMMar 2026
- -$169.77M-437.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -144.3% | -131.4% | +12.9 pp |
| 1 year | +92.3% | -3259.9% | -3352.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (6.89M) USD
- Year-over-year change
- +92.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.89M) | +92.3% |
| FY2024 | 2024-12-31 | (88.98M) | +15.0% |
| FY2023 | 2023-12-31 | (104.7M) | -3.6% |
| FY2022 | 2022-12-31 | (101.07M) | -17.8% |
| FY2021 | 2021-12-31 | (85.81M) | — |
Net Income vs competitors
How STOK compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -437.7% is the lowest of 6, against a peer median of -51.2%.
- Net income amounts to 529.2% of revenue for STOK, versus a peer median of 255.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -€45.62M EUR | -51.2% | — | 339.4% | |
| LTM Mar 2026 | -$69.71M USD | -24.0% | — | — | |
| LTM Mar 2026 | -$85.17M USD | — | — | 9243.0% | |
| LTM Jun 2026 | -$85.43M USD | +78.6% | — | 54.7% | |
| LTM Mar 2026 | -$169.77M USD | -437.7% | — | 529.2% | |
| LTM Mar 2026 | -$183.59M USD | -63.4% | — | 255.7% | |
| LTM Sep 2026 | -$546.15M USD | -113.1% | — | 56.9% | |
| Peer median (excluding STOK) | — | -51.2% | — | 255.7% | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 54.17M | 77.84M | 82.23M | 89.13M | 137.92M |
| Selling, General & Admin | 31.9M | 38.92M | 41.32M | 48.79M | 67.09M |
| Operating Expenses | 86.07M | 116.76M | 123.55M | 137.93M | 205.01M |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| EBITDA | (84.83M) | (99.52M) | (102.23M) | (86.8M) | (5.12M) |
| EBITDA Margin | — | -802.3% | -1164.4% | -237.5% | -2.8% |
| Operating Income | (86.07M) | (104.36M) | (114.77M) | (101.37M) | (20.59M) |
| Operating Margin | — | -841.2% | -1307.2% | -277.3% | -11.2% |
| Interest Income | 120K | 3.12M | 9.91M | 12.64M | 13.77M |
| Interest Expense | 0 | 0 | 0 | 0 | 9K |
| Other Income / Expenses | 260K | 3.29M | 10.07M | 12.39M | 13.71M |
| Income Before Tax | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Pre-Tax Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Net Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| EPS (Basic) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| EPS (Diluted) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| Weighted Avg Shares | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
| Weighted Avg Shares (Diluted) | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.